nach oben

Erschienen in:

01.12.2007 | Review

Mammographic density, breast cancer risk and risk prediction

verfasst von: Celine M Vachon, Carla H van Gils, Thomas A Sellers, Karthik Ghosh, Sandhya Pruthi, Kathleen R Brandt, V Shane Pankratz

Erschienen in: Breast Cancer Research | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

In this review, we examine the evidence for mammographic density as an independent risk factor for breast cancer, describe the risk prediction models that have incorporated density, and discuss the current and future implications of using mammographic density in clinical practice. Mammographic density is a consistent and strong risk factor for breast cancer in several populations and across age at mammogram. Recently, this risk factor has been added to existing breast cancer risk prediction models, increasing the discriminatory accuracy with its inclusion, albeit slightly. With validation, these models may replace the existing Gail model for clinical risk assessment. However, absolute risk estimates resulting from these improved models are still limited in their ability to characterize an individual's probability of developing cancer. Promising new measures of mammographic density, including volumetric density, which can be standardized using full-field digital mammography, will likely result in a stronger risk factor and improve accuracy of risk prediction models.

Nur mit Berechtigung zugänglich

Johns PC, Yaffe MJ: X-ray characterisation of normal and neoplastic breast tissues. Phys Med Biol. 1987, 32: 675-695. 10.1088/0031-9155/32/6/002.CrossRefPubMed

Egan RL: Breast Imaging: Diagnosis and Morphology of Breast Diseases. 1988, Philadelphia: WB Saunders Company

McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1159-1169. 10.1158/1055-9965.EPI-06-0034.CrossRefPubMed

Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995, 87: 1622-1629. 10.1093/jnci/87.21.1622.CrossRefPubMed

Pankow JS, Vachon CM, Kuni CC, King RA, Arnett DK, Grabrick DM, Rich SS, Anderson VE, Sellers TA: Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst. 1997, 89: 549-556. 10.1093/jnci/89.8.549.CrossRefPubMed

Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, et al: Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007, 356: 227-236. 10.1056/NEJMoa062790.CrossRefPubMed

Levy-Lahad E, Friedman E: Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007, 96: 11-15. 10.1038/sj.bjc.6603535.CrossRefPubMedPubMedCentral

Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD: Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005, 6: 798-808. 10.1016/S1470-2045(05)70390-9.CrossRefPubMed

Torres-Mejia G, De Stavola B, Allen DS, Perez-Gavilan JJ, Ferreira JM, Fentiman IS, Dos Santos Silva I: Mammographic features and subsequent risk of breast cancer: a comparison of qualitative and quantitative evaluations in the Guernsey prospective studies. Cancer Epidemiol Biomarkers Prev. 2005, 14: 1052-1059. 10.1158/1055-9965.EPI-04-0717.CrossRefPubMed

10.

Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG: A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control. 1995, 6: 431-438. 10.1007/BF00052183.CrossRefPubMed

11.

Maskarinec G, Pagano I, Chen Z, Nagata C, Gram IT: Ethnic and geographic differences in mammographic density and their association with breast cancer incidence. Breast Cancer Res Treat. 2007, 104: 47-56. 10.1007/s10549-006-9387-5.CrossRefPubMed

12.

Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC: Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. 2003, 12: 332-338.PubMed

13.

Vachon CM, Brandt KR, Ghosh K, Scott CG, Maloney SD, Carston MJ, Pankratz VS, Sellers TA: Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007, 16: 43-49. 10.1158/1055-9965.EPI-06-0738.CrossRefPubMed

14.

Maskarinec G, Pagano I, Lurie G, Wilkens LR, Kolonel LN: Mammographic density and breast cancer risk: the multiethnic cohort study. Am J Epidemiol. 2005, 162: 743-752. 10.1093/aje/kwi270.CrossRefPubMed

15.

Brisson J, Merletti F, Sadowsky NL, Twaddle JA, Morrison AS, Cole P: Mammographic features of the breast and breast cancer risk. Am J Epidemiol. 1982, 115: 428-437.CrossRefPubMed

16.

Brisson J, Morrison AS, Kopans DB, Sadowsky NL, Kalisher L, Twaddle JA, Meyer JE, Henschke CI, Cole P: Height and weight, mammographic features of breast tissue, and breast cancer risk. Am J Epidemiol. 1984, 119: 371-381.CrossRefPubMed

17.

Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, Yaffe M, Minkin S: Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006, 15: 2086-2092. 10.1158/1055-9965.EPI-06-0345.CrossRefPubMed

18.

Lam PB, Vacek PM, Geller BM, Muss HB: The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont. Cancer. 2000, 89: 369-375. 10.1002/1097-0142(20000715)89:2<369::AID-CNCR23>3.0.CO;2-J.CrossRefPubMed

19.

Warren R: Hormones and mammographic breast density. Maturitas. 2004, 49: 67-78. 10.1016/j.maturitas.2004.06.013.CrossRefPubMed

20.

Duffy SW, Jakes RW, Ng FC, Gao F: Interaction of dense breast patterns with other breast cancer risk factors in a case-control study. Br J Cancer. 2004, 91: 233-236.PubMedPubMedCentral

21.

Boyd NF, Lockwood GA, Martin LJ, Knight JA, Jong RA, Fishell E, Byng JW, Yaffe MJ, Tritchler DL: Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst. 1999, 91: 1404-1408. 10.1093/jnci/91.16.1404.CrossRefPubMed

22.

Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K: Mammographic breast density and family history of breast cancer. J Natl Cancer Inst. 2003, 95: 556-558.CrossRefPubMed

23.

Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, Carney PA: Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control. 2006, 17: 1281-1290. 10.1007/s10552-006-0071-1.CrossRefPubMedPubMedCentral

24.

Saftlas AF, Wolfe JN, Hoover RN, Brinton LA, Schairer C, Salane M, Szklo M: Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol. 1989, 129: 518-526.CrossRefPubMed

25.

Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, et al: Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res. 2006, 66: 1866-1872. 10.1158/0008-5472.CAN-05-3368.CrossRefPubMed

26.

van Gils CH, Hendriks JH, Otten JD, Holland R, Verbeek AL: Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev. 2000, 9: 105-111. 10.1097/00008469-200004000-00006.CrossRefPubMed

27.

Herrinton LJ, Saftlas AF, Stanford JL, Brinton LA, Wolfe JN: Do alcohol intake and mammographic densities interact in regard to the risk of breast cancer?. Cancer. 1993, 71: 3029-3035. 10.1002/1097-0142(19930515)71:10<3029::AID-CNCR2820711024>3.0.CO;2-K.CrossRefPubMed

28.

Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ: Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995, 87: 670-675. 10.1093/jnci/87.9.670.CrossRefPubMed

29.

Brisson J, Morrison AS, Khalid N: Mammographic parenchymal features and breast cancer in the breast cancer detection demonstration project. J Natl Cancer Inst. 1988, 80: 1534-1540. 10.1093/jnci/80.19.1534.CrossRefPubMed

30.

Vacek PM, Geller BM: A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev. 2004, 13: 715-722.PubMed

31.

Maskarinec G, Meng L: A case-control study of mammographic densities in Hawaii. Breast Cancer Res Treat. 2000, 63: 153-161. 10.1023/A:1006486319848.CrossRefPubMed

32.

Jakes RW, Duffy SW, Ng FC, Gao F, Ng EH: Mammographic parenchymal patterns and risk of breast cancer at and after a prevalence screen in Singaporean women. Int J Epidemiol. 2000, 29: 11-19. 10.1093/ije/29.1.11.CrossRefPubMed

33.

Maskarinec G, Nagata C, Shimizu H, Kashiki Y: Comparison of mammographic densities and their determinants in women from Japan and Hawaii. Int J Cancer. 2002, 102: 29-33. 10.1002/ijc.10673.CrossRefPubMed

34.

Egan RL, Mosteller RC: Breast cancer mammography patterns. Cancer. 1977, 40: 2087-2090. 10.1002/1097-0142(197711)40:5<2087::AID-CNCR2820400516>3.0.CO;2-3.CrossRefPubMed

35.

Maskarinec G, Pagano I, Lurie G, Kolonel LN: A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006, 15: 732-739. 10.1158/1055-9965.EPI-05-0798.CrossRefPubMed

36.

Whitehead J, Carlile T, Kopecky KJ, Thompson DJ, Gilbert FI, Present AJ, Threatt BA, Krook P, Hadaway E: The relationship between Wolfe's classification of mammograms, accepted breast cancer risk factors, and the incidence of breast cancer. Am J Epidemiol. 1985, 122: 994-1006.CrossRefPubMed

37.

Sala E, Warren R, McCann J, Duffy S, Day N, Luben R: Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen. 1998, 5: 207-212.CrossRefPubMed

38.

van Gils CH, Otten JD, Verbeek AL, Hendriks JH: Mammographic breast density and risk of breast cancer: masking bias or causality?. Eur J Epidemiol. 1998, 14: 315-320. 10.1023/A:1007423824675.CrossRefPubMed

39.

Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004, 159: 882-890. 10.1093/aje/kwh101.CrossRefPubMed

40.

Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996, 15: 361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.CrossRefPubMed

41.

Wald NJ, Hackshaw AK, Frost CD: When can a risk factor be used as a worthwhile screening test?. BMJ. 1999, 319: 1562-1565.CrossRefPubMedPubMedCentral

42.

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989, 81: 1879-1886. 10.1093/jnci/81.24.1879.CrossRefPubMed

43.

Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS: Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999, 91: 1541-1548. 10.1093/jnci/91.18.1541.CrossRefPubMed

44.

National Cancer Institute breast cancer risk assessment tool. [http://www.cancer.gov/bcrisktool/]

45.

Elmore JG, Fletcher SW: The risk of cancer risk prediction: "What is my risk of getting breast cancer"?. J Natl Cancer Inst. 2006, 98: 1673-1675.CrossRefPubMed

46.

Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA: Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001, 93: 358-366. 10.1093/jnci/93.5.358.CrossRefPubMed

47.

Tice JA, Cummings SR, Ziv E, Kerlikowske K: Mammographic breast density and the gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005, 94: 115-122. 10.1007/s10549-005-5152-4.CrossRefPubMed

48.

Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, Tice JA, Buist DS, Geller BM, Rosenberg R, et al: Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006, 98: 1204-1214.CrossRefPubMed

49.

Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH: Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006, 98: 1215-1226.CrossRefPubMed

50.

Highnam R, Pan X, Warren R, Jeffreys M, Davey Smith G, Brady M: Breast composition measurements using retrospective standard mammogram form (SMF). Phys Med Biol. 2006, 51: 2695-2713. 10.1088/0031-9155/51/11/001.CrossRefPubMed

51.

Marias K, Behrenbruch C, Highnam R, Parbhoo S, Seifalian A, Brady M: A mammographic image analysis method to detect and measure changes in breast density. Eur J Radiol. 2004, 52: 276-282. 10.1016/j.ejrad.2004.02.014.CrossRefPubMed

52.

Pawluczyk O, Augustine BJ, Yaffe MJ, Rico D, Yang J, Mawdsley GE, Boyd NF: A volumetric method for estimation of breast density on digitized screen-film mammograms. Med Phys. 2003, 30: 352-364. 10.1118/1.1539038.CrossRefPubMed

53.

van Engeland S, Snoeren PR, Huisman H, Boetes C, Karssemeijer N: Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging. 2006, 25: 273-282. 10.1109/TMI.2005.862741.CrossRefPubMed

54.

Shepherd JA, Herve L, Landau J, Fan B, Kerlikowske K, Cummings SR: Novel use of single X-ray absorptiometry for measuring breast density. Technol Cancer Res Treat. 2005, 4: 173-182.CrossRefPubMed

55.

Kerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R: Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst. 2007, 99: 386-395. 10.1093/jnci/djk066.CrossRefPubMed

56.

Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004, 96: 218-228.CrossRefPubMed

57.

Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K: Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 2090-2095.PubMed

58.

Boyd NF, Jensen HM, Cooke G, Han HL, Lockwood GA, Miller AB: Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Reference Pathologists of the Canadian National Breast Screening Study. Eur J Cancer Prev. 2000, 9: 15-24. 10.1097/00008469-200002000-00003.CrossRefPubMed

59.

Gill JK, Maskarinec G, Pagano I, Kolonel LN: The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort. Breast Cancer Res. 2006, 8: R30-10.1186/bcr1507.CrossRefPubMedPubMedCentral

60.

Aiello EJ, Buist DS, White E, Porter PL: Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2005, 14: 662-668. 10.1158/1055-9965.EPI-04-0327.CrossRefPubMed

61.

Hobson K: Density danger: women with dense breasts have a greater likelihood of cancer. US News & World Report. Posted February 4, 2007, [http://http://health.usnews.com/usnews/health/articles/070204/12breast.htm]

62.

Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA: Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 2000, 11: 653-662. 10.1023/A:1008926607428.CrossRefPubMed

63.

Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, et al: Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002, 347: 886-894. 10.1056/NEJMoa013390.CrossRefPubMed

64.

Wolfe JN: Breast patterns as an index for developing breast cancer. AJR Am J Roentgenol. 1976, 126: 1130-1137.CrossRefPubMed

65.

Berg WA, Campassi C, Langenberg P, Sexton MJ: Breast Imaging Reporting and Data System: inter- and intra-observer variability in feature analysis and final assessment. AJR Am J Roentgenol. 2000, 174: 1769-1777.CrossRefPubMed

66.

Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ: The quantitative analysis of mammographic densities. Phys Med Biol. 1994, 39: 1629-1638. 10.1088/0031-9155/39/10/008.CrossRefPubMed

Titel: Mammographic density, breast cancer risk and risk prediction
verfasst von: Celine M Vachon
Carla H van Gils
Thomas A Sellers
Karthik Ghosh
Sandhya Pruthi
Kathleen R Brandt
V Shane Pankratz
Publikationsdatum: 01.12.2007
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 6/2007
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1829

Neu im Fachgebiet Onkologie

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Identification of a novel truncating PALB2mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women

The protective side of progesterone

Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-α mice

The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer